Skip to main content
SpringerLink
Log in

Treatment of HER2-Overexpressing Metastatic Breast Cancer

  • Chapter
  • First Online:
Breast Disease

  • 1621 Accesses

Abstract

Metastatic breast cancer (MBC) overexpressing human epidermal growth factor receptor-2 (HER2) once had an overall worse prognosis, but therapies targeting HER2 have altered the natural course of HER2-positive disease. The initial success of trastuzumab in improving survival rates led to the clinical development of lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). HER2 protein overexpression and/or gene amplification remains the most important predictive factor for response to HER2-targeted therapies. The optimal duration of chemotherapy (CT) is at least 4–6 months (or longer) and/or to the time of maximal response, depending on toxicity and the absence of progression. HER2-targeted therapy can continue until progression or unacceptable toxicity. For patients with estrogen receptor–positive/progesterone receptor–positive breast cancer who are not good candidates for CT or wish to avoid the toxicity of CT, initial therapy with hormone therapy in combination with HER2-targeted therapy is a reasonable option. However, because the addition of HER2 therapy to endocrine therapy does not improve overall survival (OS), patients with low-volume disease, a long disease-free interval, indolent disease, or significant comorbidities are also candidates for endocrine therapy alone. For patients who relapse and were previously treated with adjuvant anti-HER2 therapy, the resumption of systemic treatment that includes HER2 blockade is recommended. As in the first-line setting, multiple choices are available for second- and third-line therapy. Successful targeting of HER2 has improved outcomes in HER2-positive breast cancer, but treatment resistance and brain metastases remain a problem. Ongoing studies are evaluating novel therapeutic approaches to overcome primary and secondary drug resistance in HER2-positive tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Comprehensive Cancer Network. NCCN Clinic Practice Guidelines in Oncology (NCCN Guideline), Breast Cancer. Version 1.0 2016. www.nccn.org.

  2. Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, et al. HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol Hematol. 2015;95(1):78–87. doi:10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20.

    Article  CAS  PubMed  Google Scholar 

  3. Esteva FJ, Miller KD, Teicher BA. What can we learn about antibody-drug conjugates from the T-DM1 experience? Am Soc Clin Oncol Educ Book. 2015;35:e117–25.

    Article  Google Scholar 

  4. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.

    Article  CAS  PubMed  Google Scholar 

  5. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  CAS  PubMed  Google Scholar 

  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  PubMed  Google Scholar 

  7. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264–71.

    Article  CAS  PubMed  Google Scholar 

  8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

    Article  CAS  PubMed  Google Scholar 

  9. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol. 2009;27(12):1999–2006.

    Article  Google Scholar 

  10. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(6):976–83.

    Article  CAS  PubMed  Google Scholar 

  11. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28(20):3366–79.

    Article  CAS  PubMed  Google Scholar 

  12. Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 2011;11:103.

    Article  CAS  PubMed  Google Scholar 

  13. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for her2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965–72.

    Article  CAS  PubMed  Google Scholar 

  14. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with her2-gene-amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens. J Clin Oncol. 2011;29:149–56.

    Article  CAS  PubMed  Google Scholar 

  15. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with her-2–overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–92.

    Article  CAS  PubMed  Google Scholar 

  16. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24(25):4107–15.

    Article  CAS  PubMed  Google Scholar 

  17. Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm. 2008;65(18):1703–10.

    Article  CAS  PubMed  Google Scholar 

  18. Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer. J Clin Oncol. 2013;31:1947–53.

    Article  CAS  PubMed  Google Scholar 

  19. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574–83.

    Article  CAS  PubMed  Google Scholar 

  20. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317–28.

    Article  CAS  PubMed  Google Scholar 

  21. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, et al. HER2 dimerization inhibitor pertuzumab – mode of action and clinical data in breast cancer. Breast Care (Basel). 2013;8(1):49–55.

    Article  Google Scholar 

  22. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, CLEOPATRA Study Group, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

    Article  CAS  PubMed  Google Scholar 

  23. Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.

    Article  CAS  PubMed  Google Scholar 

  24. Panowksi S, Bhakta S, Raab H, Polakis P, Jagath R, Junutula JG. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34–45.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.

    Article  CAS  PubMed  Google Scholar 

  26. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437–47.

    Article  CAS  PubMed  Google Scholar 

  27. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157.

    Article  CAS  PubMed  Google Scholar 

  28. Ellis PA, Barrios CH, Eiermannc W, Toi M, Im YH, Conte PF, et al. Phase III, randomized study of T-DM1 ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. J Clin Oncol. 33, 2015 (suppl; abstr 507).

    Google Scholar 

  29. Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yardley DA, Noguchi S, Pritchard KI, Burris 3rd HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hurvitz SA, Dalenc F, Campone M, O’Regan RM, Tjan-Heijnen VC, Gligorov J, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013;141(3):437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. SABCS December 2014, abs S6-01).

    Google Scholar 

  33. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer: results of the eLEcTRA trial. Breast. 2012;21:27–33.

    Article  CAS  PubMed  Google Scholar 

  34. Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2 hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15:122–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30:2585–92.

    Article  CAS  PubMed  Google Scholar 

  36. PHEREXA. A study of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer https://clinicaltrials.gov/ct2.

  37. Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncol. 2014;10(3):443–56.

    Article  CAS  PubMed  Google Scholar 

  38. Rimawi MF, De Angelis C, Schiff R. Resistance to anti-HER2 therapies in breast cancer. Am Soc Clin Oncol Educ Book. 2015;35:e157–64.

    Article  Google Scholar 

  39. André F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91.

    Article  PubMed  Google Scholar 

  40. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with her-2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15:924–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. T-DM1 for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  PubMed  Google Scholar 

  42. Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of T-DM1 (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014;120(5):642–51.

    Article  CAS  PubMed  Google Scholar 

  43. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, on behalf of the American Society of Clinical Oncology, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078–99.

    Article  CAS  PubMed  Google Scholar 

  44. Korkola JE, Liu M, Liby T, Heiser L, Feiler H, Gray JW. Detrimental effects of sequential compared to concurrent treatment of pertuzumab plus T-DM1 in HER2+ breast cancer cell lines. SABCS. 2014, [S6–07].

    Google Scholar 

  45. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, RECIST CRITERIA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  47. Harbeck N, Huang CS, Hurvitz S, Harbeck N, Huang CS, Hurvitz S, et al. Randomized phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1. Poster P5-19-01 presented at the San Antonio Breast Cancer Symposium (SABCS) 2014 Congress, San Antonio, Texas. 9–13 December 2014.

    Google Scholar 

  48. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32(32):3626–33.

    Article  CAS  PubMed  Google Scholar 

  49. Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. T-DM1 versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99.

    Article  CAS  PubMed  Google Scholar 

  50. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22:2227–33.

    Article  CAS  PubMed  Google Scholar 

  51. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:2100–8.

    Article  PubMed  Google Scholar 

  52. Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS, et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):1132–40.

    Article  PubMed  Google Scholar 

  53. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349–51.

    CAS  PubMed  Google Scholar 

  54. Hans-Joachim S, Manfred S, Amina W, Helga B, Nadia H, Volker H. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs. 2007;18:23–8.

    Article  Google Scholar 

  55. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92.

    Article  CAS  PubMed  Google Scholar 

  56. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43.

    Article  CAS  PubMed  Google Scholar 

  57. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452–9.

    Article  CAS  PubMed  Google Scholar 

  58. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.

    Article  CAS  PubMed  Google Scholar 

  59. Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33:1564–73.

    Article  CAS  PubMed  Google Scholar 

  60. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. T-DM1 (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26:113–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, et al. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Ann Oncol. 2013;24:2985–9.

    Article  PubMed  Google Scholar 

  62. Rachel A, Freedman RA, Gelman RS, Wefel JS, KropI IE, Melisko ME, et al. TBCRC 022: phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). J Clin Oncol 32:5s, 2014 (suppl; abstr 528).

    Google Scholar 

  63. Ferrario C, Welch S, Chaves JM, Luke N. Walker LN, Ian E, et al. ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). J Clin Oncol. 33; 2015 (suppl; abstr 612).

    Google Scholar 

  64. NCT01921335. ARRY-380 + Trastuzumab for breast cancer with brain metastases. https://clinicaltrials.gov/ct2/.

  65. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139(1):13–22.

    Article  CAS  PubMed  Google Scholar 

  66. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505–16.

    Article  CAS  PubMed  Google Scholar 

  67. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003;284:122–30.

    Article  CAS  PubMed  Google Scholar 

  68. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71:1871–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.

    Article  CAS  PubMed  Google Scholar 

  70. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13:224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7), e24720.

    Article  PubMed  PubMed Central  Google Scholar 

  73. PANACEA. Anti-PD-1 monoclonal antibody in advanced, Trastuzumab-resistant, HER2-positive breast cancer. https://clinicaltrials.gov/ct2/.

  74. Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol Pharm. 2015 [Epub ahead of print].

    Google Scholar 

  75. Verheijden G, Beusker P, Ubink R, Lee M, Groothuis P, Goedings PJ, et al. Toward clinical development of SYD985, a novel her2-targeting antibody–drug conjugate (adc) [abstract 626]. J Clin Oncol. 2014;32(suppl).

    Google Scholar 

  76. Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol. 2011;43(3):236–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Istanbul University Istanbul Medical Faculty, Institute of Oncology, Istanbul, Turkey

    Adnan Aydiner MD

Authors
  1. Adnan Aydiner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Aydiner MD .

Editor information

Editors and Affiliations

  1. Inst of Oncology,Ist Tıp Fak, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. General Surgery, Istanbul Univ Istanbul Fac of Med, Istanbul, Turkey

    Abdullah İgci

  3. Breast Surgery,, Magee-Womens Hospital, Pittsburg, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Aydiner, A. (2016). Treatment of HER2-Overexpressing Metastatic Breast Cancer. In: Aydiner, A., İgci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-26012-9_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26012-9_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26010-5

  • Online ISBN: 978-3-319-26012-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation